Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of TETRALITE Influenza Vaccine in Healthy Adults
NCT06294262Phase 2Active, not recruiting
- Sponsor
- LiteVax BV
- Start
- Jan 2024
- Primary completion
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TETRALITE in influenza, sponsored by LiteVax BV. Started Jan 2024; status: active, not recruiting.
02
Drugs
TETRALITE
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06294262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06294262.